Navigation Links
VitaPath Genetics Raises $6M in Series A Round
Date:9/10/2009

FOSTER CITY, Calif., Sept. 10 /PRNewswire/ -- VitaPath Genetics, a molecular diagnostics company, announced today that it has closed a $6 million series A round of funding led by MDV-Mohr Davidow Ventures. VitaPath was originally seeded by X/Seed Capital, which also co-invested in the Series A. Concurrent with the financing MDV's Michael Goldberg and X/Seed's Michael Borrus took seats on the company's board.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO)

VitaPath Genetics develops molecular diagnostics to help patients and their doctors correct genetic mutations that can result in serious but preventable diseases. The company's initial focus is a validated genetic test for Spina Bifida, a common birth defect that can be avoided with high dose folic acid therapy under the care of a physician. The financing proceeds will be used to complete the validation of the company's first assay and prepare for commercial launch.

"VitaPath Genetics addresses a significant and underserved area of medicine - understanding and treating preventable diseases. Whereas most medicine is delivered after the fact, VitaPath provides actionable diagnostics to identify and prevent those most at risk from developing a disease or condition," Goldberg explained. "Diagnostics such as those developed by the VitaPath team will play a key role in achieving the nation's goal of preventing disease, improving patient care and reducing healthcare costs."

VitaPath Genetics CEO Bruce Cohen added, "We are delighted to have MDV and X/Seed support the development of a whole new generation of actionable genetic assays that are based on solid science. Our unique approach to discovery and validation, originally developed in the laboratory of Jasper Rine at UC/Berkeley, will make it possible to identify and safely remediate mutations that would otherwise impair health."

About VitaPath Genetics

VitaPath Genetics develops molecular diagnostics to help patients and their doctors correct genetic mutations that can result in serious, but preventable, disease. The company's initial focus is a validated genetic test for Spina Bifida, a common birth defect that can be avoided with high dose folic acid therapy under the care of a physician.

For more information visit: www.vpgenetics.com.

About MDV-Mohr Davidow Ventures

MDV has been a leading Silicon Valley venture capital firm for more than 25 years. The firm funds and mentors entrepreneurs, scientists and young companies involved in redefining business, technology and medicine. MDV invests around three major themes: Personalizing Medicine; Powering the Planet; and Driving the Digital World. The firm partners with entrepreneurs seeking to transform healthcare through the use of more meaningful and personalized information. Category-leading life science companies funded by MDV include: Adamas; Artemis Health; CardioDx; Corventis; Crescendo Bioscience; iRhythm; Navigenics; Pacific Bioscience; ParAllele (AFFX); RainDance Technologies; Tethys Bioscience; and Ventus Medical. MDV has $2 billion dollars under management. For more information visit: http://www.mdv.com.

About X/Seed Capital

X/Seed Capital is an independent, seed-focused, venture fund providing de-novo start-up capital for entrepreneurs pursuing breakthrough innovation. X/Seed was founded in 2006 and is based in California's Silicon Valley. For more information visit: http://www.xseedcap.com.


'/>"/>
SOURCE MDV-Mohr Davidow Ventures
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The American Society of Human Genetics Hosts 59th Annual Meeting
2. Viral Genetics Completes Second Major Debt Conversion
3. The HRSA Genetics Collaboratives are Bringing Genetic and Newborn Screening Services to Local Communities Around the United States
4. Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
5. March of Dimes Celebrates 50th Anniversary of Genetics Short Course
6. Teen Behaviors Stem From Genetics, Environment
7. Interleukin Genetics Announces Strategic Divestment of Alan James Group
8. BioInformatics, LLC New Report - Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations
9. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
10. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
11. Ambry Genetics Announces Launch of Chromosomal Microarray to Offer Whole Genome Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... TX (PRWEB) , ... August 23, 2017 , ... ... in the healthcare industry, made the 2017 Inc. 5000 with a three-year ... of the nation’s fastest-growing private companies and comprises the most comprehensive look at ...
(Date:8/23/2017)... Francisco, CA (PRWEB) , ... August 23, 2017 , ... ... proud to announce a new blog archive organized month-by-month. The new rotation of archived ... treatments. Local Bay Area residents searching information about hair transplantation can review details online ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... of unique masks and serums that perfectly fuse the beauty of naturally derived ... the 2017 Indie Beauty Expo on August 23rd & 24th in New York ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Each of the past six years, Lightning Labels ... pictures of these labels and stickers, demonstrating the variety and creativity of their designs. Submissions ... label images came in. Now, it's time to announce the winners of the sixth annual ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection of ... “Wilderness Voices” is the creation of published author, Martha McKown, an ordained United ... inspired as a very young child when her older sisters studied High School literature. ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
Breaking Medicine Technology: